DB-1305/BNT325

DRUG2 trials

Sponsors

DualityBio Inc.

Conditions

Advanced Solid TumorSolid Tumors

Phase 1

First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors

RecruitingNCT05438329

DualityBio Inc.Advanced Solid Tumor

Start: 2022-07-19End: 2025-06-30Target: 1123Updated: 2025-02-27

Phase 2

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors

RecruitingNCT06953089

DualityBio Inc.Solid Tumors

Start: 2025-07-18End: 2030-06-30Target: 492Updated: 2026-02-06

Related Papers

Abstract A134: TROP-2-Targeted ADC DB-1305/BNT325 Demonstrates Preclinical Efficacy and Early Clinical Activity in Patients with Diffuse Pleural Mesothelioma

Molecular Cancer Therapeutics2025-10-22

Abstract 648: Activity of BNT327/PM8002 (PD-L1 x VEGF-A bispecific antibody) in combination with BNT325/DB-1305 (TROP2 ADC) in solid tumors: Early preclinical and clinical evidence to support BNT327 + ADC combinations

Cancer Research2025-04-211 citations

Abstract CT248: First in human trial of DB1305 in patients with advanced malignant solid tumors

Cancer Research2023-04-142 citations